HOME >> BIOLOGY >> NEWS
Novel antiviral drug concept targets number of human viruses

protein would kill the cell," says Priscilla A. Schaffer, Ph.D., chair of microbiology and senior author on the study. "We've discovered that's not true -- by inhibiting a specific type of cellular enzyme, we've been able to completely block all viral activity without damaging the cells."

The pivotal enzymes are called cyclin-dependent kinases, or cdks. Cells use cdks, along with other proteins, to drive and coordinate cell division. Many viruses, too, rely on cellular cdks for their replication.

The Penn scientists were aware that Laurent Meijer, Ph.D., and his colleagues at the Centre National de la Recherche Scientifique in Roscoff, France, had developed and characterized a variety of cdk-specific inhibitors. With Meijer's assistance, they introduced his inhibitors into HSV-infected cells to test their antiviral theory. What they found was that viral replication ceased while the cells continued to be healthy.

Since the cells depend on cdks for their division but not for many other essential functions, they simply stop dividing in the presence of the drugs. But HSV depends absolutely on cdks for at least three steps in its life cycle, as is likely the case for other viruses, making it vulnerable to cdk inhibitors in multiple ways.

Additionally, the focused reliance of the viruses on cdks, combined with the fact that cdks are cellular, not viral, proteins, strongly suggests that the viruses will have a vanishingly small chance of mutating to develop resistance to cdk inhibitors.

Among the strains of virus completely inactivated by the cdk inhibitors in the Penn experiments were HSV-1 and HSV-2, which chronically infect 80 percent and 20 percent of the world's population respectively and are responsible for painful oral, and genital lesions, themselves a risk factor for sexually transmitted diseases and other health problems. HSV infections can also result in blindness and occasionally in fatal encephalitis.

Thomas Albrecht, Ph.
'"/>

Contact: Franklin Hoke
frank.hoke@nasw.org
215-662-2560
University of Pennsylvania School of Medicine
20-Apr-2000


Page: 1 2 3

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
(Date:1/21/2017)... Research and Markets has announced the addition of the "Global ... ... recognition biometrics market to grow at a CAGR of 19.36% during ... scenario and the growth prospects of the global voice recognition biometrics ... the revenue generated from the sales of voice recognition biometrics including ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... ... February 21, 2017 , ... The medical potential of ... use, in multiple areas of medicine, due to their differentiating characteristics. Stem cells are ... have the ability to be induced to become tissue or organic-specific cells with special ...
(Date:2/21/2017)... ... February 21, 2017 , ... VetStem Biopharma, Inc ... headquarters laboratory in Poway, California. Based upon 12 years of knowledge gained ... and consultants, VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing plant. ...
(Date:2/21/2017)... and VANCOUVER, British Columbia , Feb. ... ) today announced that apatorsen results from two randomized Phase ... Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium, held February 16 ... . Clinical data from trials in bladder and prostate cancers ... in combination with standard-of-care treatments. ...
(Date:2/21/2017)... , Feb. 21, 2017   Logicalis Healthcare Solutions ... IT solutions and managed services provider ( www.us.logicalis.com ), ... Desk for Epic. The new service will help hospital ... resources by giving physicians, nurses and other clinicians immediate ... tier-one support. This will allow hospital IT staff to ...
Breaking Biology Technology:
Cached News: